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Sonographic detection of the fallopian tube
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Objective: Some ovarian malignancies may originate in the fallopian tube. The 
feasibility of ultrasonographically visualizing the fallopian tube is presented. Methods: 
In total, 549 normal women participated in the fallopian tube visualization trial, while 
ovarian visualization was studied in 43,521. Chi-square analysis, t-tests and multivariate 
analysis determined significance and interactions. Results: Ovaries were observed in 
82.7% while fallopian tubes were detected in 77.2% of women and 85.2% of the 
time when an ovary was detected. Age, BMI or parity was not significantly different 
when one or both fallopian tubes were visualized. Elevated BMI had slightly greater 
influence than age in limiting visualization of the fallopian tubes in multivariate 
analysis. Conclusion: Fallopian tubes can often be identified sonographically. Ovarian 
visualization provides the strongest indicator favoring fallopian tube detection. 
Thus, ultrasonographic examinations for adnexal cancer could include evaluation of 
fallopian tubes even in women >60 years and in women with BMI ≥25.
First draft submitted: 21 October 2015; Accepted for publication: 22 December 2015; 
Published online: 17 May 2016
Keywords: detection • fallopian tube • ovary • ultrasound
For several years, an expanding literature 
has implicated the fallopian tube fimbria as 
the point of origin of ovarian cancer [1–10]. 
Thus, malignancy can arise from the sur-
face of the ovary, the fallopian tube and the 
mesothelial lining of the peritoneal cavity. 
Expanding the scope of surveillance to as 
many of these sources as possible in order to 
detect this disease in its earliest development 
may be of benefit. The frequency of surgi-
cally diagnosed fallopian tube malignancy 
is very rare (3.72/million women), about 
3% of adnexal malignancies (119.9/million 
malignancies) [11]. In a sample of women 
at risk for ovarian cancer due to BRCA1/2 
mutations who received risk-reducing sal-
pingo-oophorectomy, occult malignancy 
was detected in 2.5% of patients [12,13]. 
Among the occult malignancies discovered, 
the frequency of fallopian tube malignan-
cies has been reported over a wide range: 
18.8–81.8% [2,12,13]. Consequently, the pro-
portion of occult malignancies arising in 
the fallopian tube is of clinical significance. 
It is accepted that fallopian tubes are best 
visualized sonographically when thickened 
or filled with fluid due to pelvic inflamma-
tory disease, torsion, ectopic pregnancy or 
tumors [14]. Demonstration of primary car-
cinoma in the fimbria by ultrasonography 
has been reported [15]. However, the notion 
predominates that fallopian tubes, which 
are approximately 10 cm long, are not con-
sistently observable by ultrasonography in 
the absence of pathology [16], and often little 
or no effort is directed at including them in 
ultrasound studies of the adnexa. The results 
reported here show the facile visualization 
of normal fallopian tubes using transvagi-
nal sonography and attest to the feasibility 
of including the fallopian tubes in routine 
ultrasonographic gynecologic examinations.
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Methods
A sample of 549 women, enrolled in the University 
of Kentucky Ovarian Cancer Screening Program, 
was prospectively evaluated over the trial period 
January 2013–July 2014. The screening cohort 
contained 43,521 women that had prospectively 
received transvaginal ultrasound examinations of the 
ovaries in the screening program from 1987–2014. 
Approval was received from the University of Ken-
tucky Institutional Review Board. Study eligibil-
ity, exclusions, instrumentation, protocol, criteria 
for designating an abnormality, data collection and 
storage were as previously reported [17–21]. In brief, 
criteria for eligibility were: asymptomatic women 
aged ≥50 years; and, asymptomatic women aged 
≥25 years with a documented family history of ovar-
ian cancer (OvCA) in at least one primary or second-
ary relative. Fallopian tube transvaginal sonography 
(TVS) was performed exclusively using a General 
Electric Voluson 730 ProV unit (WI, USA) with a 
5–9-mHz vaginal probe to insure uniformity of 
results, and consisted of all new participants exam-
ined on this ultrasound unit during the 18-month 
trial period (January 2013–June 2014) so that the 
549 women represented 100% of the women exam-
ined on this unit. This design avoided bias due to 
a previous screening result. Ovaries and fallopian 
tubes were measured in three dimensions. Ovarian 
volume was calculated using the prolate ellipsoid 
formula (length × width × height × 0.523) [22]. Cri-
terion for positive fallopian tube visualization was a 
successful sagittal, coronal and transverse measure-
ment. Genetic testing was not included in this trial. 
All study participants completed a questionnaire 
that included medical history, surgical history, last 
menstrual period/menopausal status, hormonal use 
and family history of cancer. Women with a known 
ovarian tumor or a personal history of ovarian cancer 
were excluded from the study, as were BRCA1 and/or 
BRCA2 mutation carriers and women with a his-
tory of prior abdominal surgery. Participants in the 
screening program received free annual screening.
Identifying the fallopian tubes & ovaries with 
transvaginal ultrasonography
The transducer was introduced vaginally and placed 
in the transverse plane focused on the most fundal 
portion of the uterus. From the most superior and lat-
eral portion of the uterus, the transducer was adjusted 
so that images were acquired heading laterally to the 
right [23,24]. By continuing angling superior and right 
lateral, the fallopian tube appeared as the echoes 
headed lateral and posterior to the most distal por-
tion. Landmarks for proving structure were the tubal 
vessels located posterior and parallel to the fallopian 
tube. Width measurements were made from the most 
proximal portion of the fallopian tube to the most 
distal. In order to measure the length and depth, the 
transducer was rotated into the longitudinal plane. In 
the longitudinal view, the fallopian tube had an oval 
appearance. An identical approach was taken in pro-
gression to the left in order to visualize the opposing 
fallopian tube. Continuation of the view aspect later-
ally presented the ovarian views, which were proven 
by association with ovarian blood vessels. Power 
Doppler was used to follow vessels and establish their 
identity. Archived blinded images were all reviewed 
by a physician in order to confirm or reject findings 
of the sonographer. Only when there was agreement 
by both, were positive results accepted in this study. 
A sonographic study was terminated in the absence 
of visualization following unsuccessful sonographic 
visualization after applying pressure to at least three 
regions of the abdominal surface and observing repo-
sitioning of bowel or complaints of pain from the 
participant. In the group reported on here, none of 
the nonvisualizations were associated with observed 
fibroids or ultrasonographic shadowing that would 
prevent signal penetration. Moreover, endometriosis 
was neither reported by any participants in the non-
visualization group nor was it or resultant scarring 
evident in the ultrasound examination. We estimate 
that approximately 5 min were added to the ultra-
sound examination when fallopian tube visualization 
occurred and approximately 10 min when visualiza-
tion could not be achieved.
Statistical methods
Significance was determined at the 0.05 level. Propor-
tions were compared using chi-square statistics, and 
t-testing was performed on parametric variables. For the 
multivariate analysis, separate logistic regression models 
were applied to the outcomes visualization of one fallo-
pian tube, or both tubes, or at least one tube, and each 
regressed against age and BMI. In all cases, responses 
were clustered at the individual woman level. The latter 
variables were first entered into the model as raw values 
(linear response for each variable) and then entered as a 
class variable: age in categories <60 years, 60–69 years 
and ≥70 years, and BMI in categories as <25, 25–29 and 
≥30. The three outcomes of interest were: only one fal-
lopian tube visualized, both fallopian tubes visualized 
and at least one fallopian tube visualized.
Results
The ultrasonographic associations between ovary, 
fallopian tube with fimbria and uterus are shown in 
Figure 1. Faint echogenicity at the tubal–ovarian ter-
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minus reveals the fimbriated ends in the cases exam-
ined. Axial proportions differ in paired perspectives. 
In terms of fallopian tube and ovarian visualization, 
the groups in which ovaries or fallopian tubes were 
not visualized were significantly older and had a 
greater BMI (p < 0.001); however, they did not differ 
with respect to parity (Table 1). There were no signifi-
cant differences in women that had one or both fal-
lopian tubes visualized with respect to age (63.1 ± 0.5 
vs 62.1 ± 0.6), BMI (24.5 ± 0.3 vs 26.2 ± 0.3) or 
parity (1.8 ± 0.01 vs 1.9 ± 0.6). Ovaries were observed 
in 82.7% of those examined (Table 2) and a fallopian 
tube was detected in 77.2% of the women examined 
(Table 2). When visualization of the ovary occurred, 
the visualization success rate for detecting the fallo-
pian tube was 85.2% (Table 3) showing that the fallo-
pian tube could be detected a high percentage of the 
time (85.2%) when an ovary was detectable (Table 3).
Detection of fallopian tubes did not differ from 
the detection of the ovaries across age categories 
(Table 4: F1 vs O1, F2 vs O2 and F3 vs O3). Both 
fallopian tubes could be detected in only ∼5% of 
women ≥75 years (Table 4, F3). This low rate of 
visualization for both fallopian tubes coincided with 
low detection of both ovaries in women ≥75 years 
(Table 4). In the women surveyed for fallopian tubes, 
failure to detect the fallopian tubes ([76 + 25]/125 = 
80.8%) or ovaries ([57 + 20]/95) = 81.1%) was high-
est in women over 60 years of age (Table 4). Thus, 
age is a factor in the visualization of both the ovaries 
and fallopian tubes. An anomaly exists in the fal-
lopian tube dataset presented here, which indicates 
that detection of tubes and ovaries (one or both) is 
higher for women who are 61–74 years old as com-
pared with those that are 51–60 years old. This is not 
supported by ovarian visualization over all examina-
tions in the entire screened population (Table 4, see 
bold upper case). In Table 4, it should be noted that 
summaries for all examinations reflect results from 
repeat examinations, while summaries for women are 
for a single ultrasound examination and will account 
for the differences in the distributions of results for 
women versus examinations.
In total, 51,350 examinations were performed on 
women with a BMI <30 while 21,757 examinations 
were on women with a BMI ≥30. Approximately the 
same proportion of examinations were on women with 
BMI ≥30 who were ≤50 years old (31.1%) as were on 
those that were >50 years old (29.5%). The detection 
of the fallopian tubes did not differ from the detec-
tion of the ovaries with regard to BMI (Table 5: F1 vs 
O1, F2 vs O2 and F3 vs O3). However, the BMI dis-
tribution of women in which no fallopian tubes were 
visualized was significantly different from women in 
Figure 1. Ultrasound image of the fallopian tube. Ultrasound perspectives of the fallopian tube (yellow outline), ovary (green 
outline), uterus (red outline) and fimbria (white outline and white arrow).
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which both fallopian tubes were detected (Table 5: F1 
vs F3; p < 0.0001) as was the BMI distribution of 
women in which ovaries were not visualized as com-
pared with when both were visualized (Table 5: O1 vs 
O3; p < 0.0001), showing that a failure to detect the 
fallopian tubes ([44 + 50]/125 = 75.2%) or ovaries 
([34 + 34]/95 = 71.6%) was highest in overweight 
women (BMI ≥25) and that the detection of both fal-
lopian tubes ([72 + 25]/252 = 38.5%) or both ovaries 
([110 + 43]/349 = 43.8%) was lowest in overweight 
women, Table 5. These results indicate that BMI has 
an influence on the ability to visualize the ovaries and 
fallopian tubes; however, one or both fallopian tubes 
were still visualized in 45.7% of cases with BMI ≥25 
or about 3% less than ovarian visualization, suggest-
ing that attempts to visualize the fallopian tube in 
women with BMI ≥25 will be worthwhile.
Multivariate analysis
Since obesity can be expected to be limiting to 
longevity, multivariate analysis was performed to 
isolate the effects of age and body habitus on fal-
lopian tube visualization. Both age and BMI were 
significant predictors of the events: both fallopian 
visualized (odds ratio [OR]
AGE
: 1.038 [95% CI: 
1.017–1.060]; OR
BMI
: 1.134 [95% CI: 1.088–1.182]) 
and at least one fallopian visualized (OR
AGE
: 1.088 
[95% CI: 1.057–1.120]; OR
BMI
: 1.179 [95% CI: 
1.175–1.236]), while neither age (OR
AGE
: 1.013 
[95% CI: 0.99–1.034]) nor BMI (OR
BMI
: 1.0 
[95% CI: 0.96–1.030]) were significant predictors of 
the event only one fallopian visualized. These results 
permit the exclusion of the event only one fallopian 
tube from further considerations.
To determine if either age or BMI is more impor-
tant, it could be argued in favor of BMI because 
its p-value for the event both visualized is smaller 
than that for age, although both p-values are small 
(p < 0.0004 for age and p < 0.0001 for BMI). How-
ever, a better alternative argument relies on the C sta-
tistic. The C statistic is an indicator of how well the 
logistic model fits the data with C = 1 being a perfect 
prediction and C = 0.5 being the equivalent of guess-
ing when using the model to predict the outcome. For 
the outcome both fallopian tubes visualized, C statis-
tic
BMI
: 0.665 comes closer to the logistic model (C sta-
tistic: 0.680) with both variables than C statistic
AGE
: 
0.574 and, hence, is clearly the better of the two out-
comes tested. This is less clear for the outcome at least 
one fallopian tube visualized (C statistic
BMI
: 0.679 or 
C statistic
AGE
: 0.657) when compared with the logistic 
model for both variables (C statistic: 0.769). Thus, if 
using only one of the two variables in a logistic model, 
BMI would have the greater weight.
Table 1. Fallopian tube and ovary detection by transvaginal ultrasonography with respect to age, body habitus and 
parity.
Visualization condition n Age (years) BMI Parity 
  Mean ± SEM Median 
(range)
Mean ± SEM Median  
(range)
Mean ± SEM Median 
(range) 
Total women examined 549 63.5 ± 0.37 64 (26–85) 26.2 ± 0.21 25.1 (15.3–48.6) 1.9 ± 0.05 2 (0–7)
Women with no fallopian 
tubes visualized
125 67.1 ± 0.74* 67 (33–85) 28.6 ± 0.47* 28.7 (16.6–47.4) 2.1 ± 0.12 2 (0–7)
Women with no ovaries 
visualized
95 67.1 ± 0.88* 67 (33–85) 28.7 ± 0.55* 28.5 (16.6–47.4) 2 ± 0.13 2 (0–7)
Women with only one 
fallopian tube visualized
172 63.1 ± 0.54 63 (42–80) 24.5 ± 0.29 23.9 (17–40.4) 1.8 ± 0.09 2 (0–5)
Women with only one 
ovary visualized
105 65.7 ± 0.73 66 (50–82) 26.9 ± 0.45 26.7 (18.8–37.4) 2.1 ± 0.12 2 (0–5)
Women with one or two 
fallopian tubes visualized
424 62.5 ± 0.42 64 (26–85) 25.5 ± 0.22 24.8 (15.3–48.6) 1.8 ± 0.06 2 (0–6)
Women with one or two 
ovaries visualized
454 62.8 ± 0.41 63 (26–85) 25.7 ± 0.21 24.9 (15.3–48.6) 1.9 ± 0.06 2 (0–6)
Women with both 
fallopian tubes visualized
252 62.1 ± 0.6 63 (26–85) 26.2 ± 0.3 25.2 (15.3–48.6) 1.9 ± 0.6 2 (0–6)
Women with both ovaries 
visualized
349 61.9 ± 0.47 62 (26–85) 25.3 ± 0.24 24.5 (15.3–48.6) 1.8 ± 0.06 2 (0–6)
*p < 0.001.
SEM: Standard error of mean.
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Because the multivariate model assumes that the 
probability of visualization is linear with regard to age 
and BMI, age was broken into intervals:
•	 <60 years (n = 168);
•	 60–69 years (n = 252); 
•	 ≥70 years (n = 130). 
While BMI was broken into the intervals:
•	 <25 (n = 262);
•	 25–29 (n = 181);
•	 ≥30 (n = 107).
The multivariate model was retrofitted with these 
intervals and for the outcome that both fallopian 
tubes were visualized. It was observed that women 
aged ≥70 years differed (were worse or less likely to 
have both fallopian tubes visualized) when com-
pared with women under 60 years of age (OR: 1.84 
[95% CI: 1.125–3.011]). Comparisons of BMI showed 
that while BMI 25–29 was worse (OR: 2.451 [95% CI: 
1.655–9.082]) than BMI <25, the BMI interval ≥30 
(OR: 5.362 [95% CI: 3.166–3.011]) was even worse 
when compared with BMI <25.
When the multivariate model was retrofitted with 
these intervals for the outcome that at least one fal-
lopian tube was visualized, it was observed that the 
OR did vary by age since visualization in women 
under 60 years of age differed from visualization 
in those of age 60–69 years (OR: 2.655 [95% CI: 
1.478–4.769]) and those ≥70 years (OR: 5.315 [95% 
CI: 2.810–10.052]), while under 25 BMI differed from 
both 25–29 (OR: 2.499 [95% CI: 1.487–4.201]) and 
≥30 (OR: 7.562 [95% CI: 4.320–13.237]). Thus, the 
likelihood of visualizing at least one fallopian tube gets 
worse with both increasing age and increasing BMI.
Discussion
The work reported here presents a strong argument 
that when sonographic detection of an ovary is pos-
sible, visualization of the normal fallopian tube can 
be performed in a large majority (85%) of these cases. 
Prior work confined to younger infertility patients and 
not stratified for age, body habitus and ovarian visual-
ization reported sonographic visualization of the fallo-
pian tubes with similar frequency as reported here [25]. 
Increasing age and body habitus negatively influence 
visualizations. However, we show here that the fallo-
pian tubes can still be detected in over 60% of women 
who are >60 years of age and in women with BMI ≥25 
at a frequency that is similar to or only marginally less 
than ovarian detection (∼59%). Importantly, visual-
ization of the ovaries is the strongest factor indicat-
ing that visualization of the fallopian tubes is likely. 
In addition, the geometrical arrangements of the fal-
lopian tubes, ovaries and uterus are likely to be limit-
ing, especially when the uterus gets positioned between 
these structures or the fallopian tube bends behind the 
uterus. Because occult malignancy has been reported 
with high frequency in specimens from risk-reducing 
salpingo-oophorectomies [2,12,13], we believe that 
including the fallopian tubes in ultrasonographic sur-
veillance has the potential for detecting adnexal carci-
nomas at earlier points of onset. Ultrasound detection 
Table 2. Fallopian tube and ovary detection by 
transvaginal ultrasonography.
Visualization condition n %  p-value
Total women examined 549 100.0  
Women with no 
fallopian tubes visualized
125 22.8  
Women with no ovaries 
visualized
95 17.3 <0.05
Women with only one 
fallopian tube visualized
172 33.0  
Women with only one 
ovary visualized
105 19.1 <0.001
Women with one or two 
fallopian tubes visualized
424 77.2  
Women with one or two 
ovaries visualized
454 82.7 <0.05
Women with both 
fallopian tubes visualized
252 45.9  
Women with both 
ovaries visualized
349 63.6 <0.001
Significance testing: visualization of fallopian tubes vs ovaries by 
Chi-square.
Table 3. Detection frequency of fallopian tubes 
and ovaries by transvaginal ultrasonography.
Summary of visualization n %
Total women examined 549 100.0
Surgically absent ovaries 10 0.9
Nonvisualized ovaries 295 26.9
Ovaries detected 793 100.0
Fallopian tubes visualized 676 85.2
Total possible ovaries that could be included = 1098 (549 × 2) 
with correction for undetected and absent ovaries reducing the 
number to 305 (10 + 295) = 793 documentable ovaries present 
which becomes the maximum possible ovaries that were present 
(i.e., 100%). Fallopian tube visualization was normalized by the 
number of ovaries that were present (1098 - 305 = 793).
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of fimbrial malignancy has been reported as a proof of 
concept [15]. The work presented here provides proof of 
concept that fallopian tube visualization by ultrasound 
is very often possible. It has not yet been determined 
if malignancy detected by fallopian tube surveillance 
will lead to an advantage over early stage detection of 
malignancy achieved by monitoring only the ovary. 
However, at present it seems prudent to avoid ignor-
ing this possibility. The present report neither attempts 
to characterize, categorize or classify sonographic 
findings of the fallopian tubes, nor does it include 
abnormal findings like malignancy, but has a singular 
focus on fallopian tube detectability. The adequacy of 
ultrasound to detect primary malignancy in the ductal 
fimbria has been established [15]. Here we report that 
the 5–10 min extension of adnexal ultrasound studies 
to include fallopian tubes will frequently be successful 
and does not add a time or cost burden.
Some consideration of the origin of ovarian cancer in 
the fimbria of the fallopian tube as a model is appropri-
ate. A popular hypothesis is that invasive or serous tubal 
intraepithelial carcinoma [6] is responsible for seeding 
the peritoneal cavity with malignant cells originating 
in the fimbriated ends of the fallopian tubes [26]. A pre-
sumption of this model is that it presents only micro-
scopic disease that is expected to evade sonographic 
detection. However, just as ultrasonography can detect 
early stage malignancy in the ovary that is highly cur-
able with surgery alone [27], we hypothesize that there 
can be cases which have progressed beyond serous tubal 
intraepithelial carcinoma in the distal fallopian tube 
that will be detected by ultrasonography and represent 
an early development of disease that has a favorable 
prognosis for survival.
Not all cases of ovarian cancer are associated 
with fimbrial malignancy and this leads to several 
considerations:
•	 Not all ovarian cancers originate in the fimbria;
•	 After spreading beyond their origination point in 
the fimbria, originating foci of primary fimbrial 
malignancy disappear.
We admit that in such cases, ultrasonography of the 
distal fallopian tube will reveal little, but neither will 
histology.
However, it is possible that the proximity of the 
fimbriated end to the peritoneal cavity facilitates the 
appearance of nonovarian peritoneal malignancy. In 
these cases, including the fallopian tubes in ultrasono-
graphic studies of the adnexa may discern distal tube 
abnormalities that could identify a precursor event to 
eventual peritoneal cancer and lead to much earlier 
discovery of peritoneal disease. We assert that all too T
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many times the fallopian tubes are overlooked under 
the presumption that their detection is very unlikely. 
The work presented here shows that this presumption is 
unwarranted, and we advocate including the fallopian 
tubes in pelvic ultrasound studies.
Financial & competing interests disclosure
This work was supported by grants from the Telford Founda-
tion and the Department of Health and Human Services, Com-
monwealth of Kentucky. The authors have no other relevant 
affiliations or financial involvement with any organization or 
entity with a financial interest in or financial conflict with the 
subject matter or materials discussed in the manuscript apart 
from those disclosed.
No writing assistance was utilized in the production of this 
manuscript.
Ethical conduct of research
The authors state that they have obtained appropriate institu-
tional review board approval or have followed the principles 
outlined in the Declaration of Helsinki for all human or animal 
experimental investigations. In addition, for investigations in-
volving human subjects, informed consent has been obtained 
from the participants involved.
Executive summary
The nature of the problem
•	 Abdominal cancers can arise from the surface of the ovary, the fallopian tube and the mesothelial lining of the 
peritoneal cavity.
•	 In recent years, the fimbrial portion of the fallopian tube has been implicated in the origin of some ovarian 
and primary peritoneal malignancies.
•	 Ultrasound is recognized as effective for examining ovarian structure; however, the notion predominates that 
ultrasound is ineffective for revealing the fallopian tubes in the absence of pathology related to enlargement, 
thickening or fluid retention.
•	 The present work finds that ultrasound effectively visualizes the fallopian tubes in a very large proportion 
of normal women indicating that expanding ultrasound examinations to include the fallopian tubes as an 
additional source of malignancy may achieve detection at an early stage.
Experimental setting for the findings
•	 In total, 549 women enrolled in the University of Kentucky Ovarian Cancer Screening program (n = 43,621) 
were prospectively examined ultrasonographically for the visualization of fallopian tubes on their first 
encounter.
•	 In total, 43,621 women were prospectively examined ultrasonographically for visualization of the ovaries.
•	 The criterion for positive fallopian tube and ovarian visualization was successful measurement in all three 
dimensions.
Summary of the findings
•	 Ovaries were ultrasonographically visualized in 82.7% of the women and fallopian tubes were seen in 77.2% 
of the women.
•	 When ovaries were visualized, fallopian tubes were also seen in 85.2% of the women.
•	 The likelihood of visualizing at least one fallopian tube gets lower with both increasing age and increasing BMI 
so that detection of the ovaries and fallopian tubes was lowest after the age 60 years and when BMI was ≥25.
•	 Fallopian tubes are still detectable in >60% of women aged >60 years and in women with BMI ≥25.
Implications of the findings
•	 Attempts to detect the fallopian tubes are justified by visualization rates that parallel ovarian visualization 
rates across age and BMI, and these visualization rates are high.
•	 There is no significant burden of time or cost imposed by efforts to visualize the fallopian tubes.
Questions worthy of discussion
•	 Will ultrasonographic surveillance of the fallopian tubes lead to early detection of ovarian and primary 
peritoneal malignancies?
 – The most promising aspect of early detection led by fallopian tube surveillance is the possibility of 
becoming aware of occult primary peritoneal malignancy early in its onset.
•	 Will early detection of fimbrial malignancy offer any advantage over early detection of ovarian malignancy?
 – It is possible that stage I ovarian malignancy detected by fallopian tube surveillance will have similar great 
outcomes to stage I malignancy detected by ovarian ultrasonography. It is also possible that fimbrial 
ultrasound surveillance will usher in more cases where peritoneal tumor burden discovered operatively is 
much smaller so that it can be more completely removed surgically or effectively treated intraperitoneally.
•	 What is needed next to take advantage of fallopian tube surveillance using ultrasonography?
 – A body of knowledge must be developed to characterize abnormalities of the fimbria ultrasonographically 
and relate them to malignancy.
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